Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Niraparib Shows Superior Tissue Distribution and Efficacy in a Prostate Cancer Bone Metastasis Model Compared to Other PARP Inhibitors

Linda A. Snyder, Rajendra Damle, Shefali Patel, Jared Bohrer, Anna Fiorella, Jenny Driscoll, Rebecca Hawkins, Christopher F. Stratton, Carol D. Manning, Kanaka Tatikola, Volha Tryputsen, Kathryn Packman, Rao N.V.S. Mamidi

Mol Cancer Ther molcanther.0798.2021.

DOI: https://doi.org/10.1158/1535-7163.MCT-21-0798

Published: 02 May 2022

View article

Includes: Supplementary data

Journal Articles

Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor Activity

Mol Cancer Ther (2021) 20 (12): 2317–2328.

DOI: https://doi.org/10.1158/1535-7163.MCT-21-0367

Published: 03 December 2021

View article

Includes: Supplementary data

Journal Articles

Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active Against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate Cancer

Jonathan R. Branch, Tammy L. Bush, Vineet Pande, Peter J. Connolly, Zhuming Zhang, Ian Hickson, Janine Ondrus, Steffen Jaensch, James R. Bischoff, Georges Habineza, Geert Van Hecke, Lieven Meerpoel, Kathryn Packman, Christopher J. Parrett, Yolanda T. Chong, Marco M. Gottardis, Gilles Bignan

Mol Cancer Ther (2021) 20 (5): 763–774.

DOI: https://doi.org/10.1158/1535-7163.MCT-20-0510

Published: 01 May 2021

View article

Includes: Supplementary data

Journal Articles

Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis

Smruthi Vijayaraghavan, Lorraine Lipfert, Kristen Chevalier, Barbara S. Bushey, Benjamin Henley, Ryan Lenhart, Jocelyn Sendecki, Marilda Beqiri, Hillary J. Millar, Kathryn Packman, Matthew V. Lorenzi, Sylvie Laquerre, Sheri L. Moores

Mol Cancer Ther (2020) 19 (10): 2044–2056.

DOI: https://doi.org/10.1158/1535-7163.MCT-20-0071

Published: 02 October 2020

View article

Includes: Multimedia, Supplementary data

Journal Articles

RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis

Mol Cancer Ther (2016) 15 (5): 946–957.

DOI: https://doi.org/10.1158/1535-7163.MCT-15-0647

Published: 05 May 2016

View article

Includes: Supplementary data

Journal Articles

Abstract A156: Preclinical activity of MDM2 antagonist RO6839921, a pegylated prodrug for intravenous administration

Brian Higgins, Christian Tovar, Kelli Glen, Aruna Railkar, Zoran Filipovic, Farooq Qureshi, Binh Vu, George Ehrlich, Dan Fishlock, Lin-Chi Chen, Steven Middleton, Gwen Nichols, Kathryn Packman, Lyubomir Vassilev

Mol Cancer Ther (2015) 14 (12_Supplement_2): A156.

DOI: https://doi.org/10.1158/1535-7163.TARG-15-A156

Published: 01 December 2015

View article

Journal Articles

Abstract B55: Antitumor activity of the MDM2 antagonist RG7388.

Brian Higgins, Christian Tovar, Kelli Glenn, Antje Walz, Zoran Filipovic, Yu-E Zhang, Markus Dangl, Bradford Graves, Lyubomir Vassilev, Kathryn Packman

Mol Cancer Ther (2013) 12 (11_Supplement): B55.

DOI: https://doi.org/10.1158/1535-7163.TARG-13-B55

Published: 01 November 2013

View article

Journal Articles

Abstract B130: BRAFV600E negatively regulates the PI3K/AKT pathway in melanoma cell lines.

Brenden Chen, Christine Tardell, Brian Higgins, Kathryn Packman, John F. Boylan, Huifeng Niu

Mol Cancer Ther (2011) 10 (11_Supplement): B130.

DOI: https://doi.org/10.1158/1535-7163.TARG-11-B130

Published: 12 November 2011

View article

Journal Articles

Preclinical In vivo Evaluation of Efficacy, Pharmacokinetics, and Pharmacodynamics of a Novel MEK1/2 Kinase Inhibitor RO5068760 in Multiple Tumor Models

Sherif Daouti, Brian Higgins, Kenneth Kolinsky, Kathryn Packman, Huisheng Wang, Christine Rizzo, John Moliterni, Nicholas Huby, Nader Fotouhi, Mei Liu, Petra Goelzer, Harpreet K. Sandhu, Jia Kui Li, Aruna Railkar, David Heimbrook, Huifeng Niu

Mol Cancer Ther (2010) 9 (1): 134–144.

DOI: https://doi.org/10.1158/1535-7163.MCT-09-0601

Published: 12 January 2010

View article

Includes: Supplementary data

Journal Articles

Abstract A247: Preclinical antitumor activity of the MEK inhibitor RO5068760 in human tumor xenograft models

Higgins Brian, Kenneth Kolinsky, Sherif Daouti, Christine Rizzo, Huisheng Wang, Nicholas Huby, Huifeng Niu, Kathryn Packman

Mol Cancer Ther (2009) 8 (12_Supplement): A247.

DOI: https://doi.org/10.1158/1535-7163.TARG-09-A247

Published: 10 December 2009

View article

Journal Articles

In vivo activity of novel capecitabine regimens alone and with bevacizumab and oxaliplatin in colorectal cancer xenograft models

Kenneth Kolinsky, Ben-Quan Shen, Yu-E Zhang, Joseph Kohles, Ute Dugan, Thomas F. Zioncheck, David Heimbrook, Kathryn Packman, Brian Higgins

Mol Cancer Ther (2009) 8 (1): 75–82.

DOI: https://doi.org/10.1158/1535-7163.MCT-08-0596

Published: 12 January 2009

View article

Journal Articles

Plx4032, a selective b-raf^V600E inhibitor has potent anti-tumor activity in b-raf^V600E-bearing colorectal xenografts and shows additive effect with other chemoagents

Fei Su, Hong Yang, Brain Higgin, Jianping Chen, Kenneth Kolinsky, Kathryn Packman, David C. Heimbrook

Mol Cancer Ther (2007) 6 (11_Supplement): A252.

Published: 01 November 2007

View article

Journal Articles

Preclinical testing of tumor and angiogenesis inhibitor R1530 in a rat prostatic adenocarcinoma model

Frank Herting, Kenneth Kolinsky, Stefan Hort, Gunther Muth, Esther Abraham, Melissa Smith, Wanping Geng, Yu-E Zhang, Christain Tovar, Kathryn Packman, Brian Higgins

Mol Cancer Ther (2007) 6 (11_Supplement): A242.

Published: 01 November 2007

View article

Journal Articles

In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials

Mol Cancer Ther (2006) 5 (11): 2644–2658.

DOI: https://doi.org/10.1158/1535-7163.MCT-06-0355

Published: 22 November 2006

View article

Journal Articles

Preclinical evaluation of tumor microvascular response to a novel antiangiogenic/antitumor agent RO0281501 by dynamic contrast-enhanced MRI at 1.5 T

Manickam Muruganandham, Mihaela Lupu, Jonathan P. Dyke, Cornelia Matei, Michael Linn, Kathryn Packman, Kenneth Kolinsky, Brian Higgins, Jason A. Koutcher

Mol Cancer Ther (2006) 5 (8): 1950–1957.

DOI: https://doi.org/10.1158/1535-7163.MCT-06-0010

Published: 23 August 2006

View article

NARROW

Niraparib Shows Superior Tissue Distribution and Efficacy in a Prostate Cancer Bone Metastasis Model Compared to Other PARP Inhibitors

Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor Activity

Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active Against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate Cancer

Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis

RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis

Abstract A156: Preclinical activity of MDM2 antagonist RO6839921, a pegylated prodrug for intravenous administration

Abstract B55: Antitumor activity of the MDM2 antagonist RG7388.

Abstract B130: BRAFV600E negatively regulates the PI3K/AKT pathway in melanoma cell lines.

Preclinical In vivo Evaluation of Efficacy, Pharmacokinetics, and Pharmacodynamics of a Novel MEK1/2 Kinase Inhibitor RO5068760 in Multiple Tumor Models

Abstract A247: Preclinical antitumor activity of the MEK inhibitor RO5068760 in human tumor xenograft models

In vivo activity of novel capecitabine regimens alone and with bevacizumab and oxaliplatin in colorectal cancer xenograft models

Plx4032, a selective b-raf^V600E inhibitor has potent anti-tumor activity in b-raf^V600E-bearing colorectal xenografts and shows additive effect with other chemoagents

Preclinical testing of tumor and angiogenesis inhibitor R1530 in a rat prostatic adenocarcinoma model

In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials

Preclinical evaluation of tumor microvascular response to a novel antiangiogenic/antitumor agent RO0281501 by dynamic contrast-enhanced MRI at 1.5 T

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only